Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03748303 · ClinicalTrials.gov registry record · Phase 1
Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study
A Phase 1 study, sponsored by University of Arizona.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03748303 is a Phase 1 study that was terminated before completion, run by University of Arizona. The registered enrollment target is 6 participants.
The verdict
NCT03748303, a Phase 1 study, was terminated before completion, sponsored by University of Arizona.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to identifying the intramuscular dose equivalent to the 4mg intravenous dose and assess its safety and tolerability as a weekly injection.
Interventions
- DRUG Allopregnanolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2022-12-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03748303
The ClinicalTrials.gov registry entry for NCT03748303 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Allopregnanolone is the first listed.
NCT03748303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03748303 about?
NCT03748303 is a clinical study titled "Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study". The purpose of this study is to identifying the intramuscular dose equivalent to the 4mg intravenous dose and assess its safety and tolerability as a weekly injection.
What is the current status of trial NCT03748303?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2019-10-01. Estimated completion is 2022-12-21.
What interventions are being tested in trial NCT03748303?
The interventions under investigation include: Allopregnanolone (DRUG).
Who is sponsoring clinical trial NCT03748303?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.